Intellectus Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.92M | Buy |
11,595
+811
| +8% | +$174K | 0.5% | 42 |
|
|
2026
Q1 | $2.35M | Buy |
10,784
+4,310
| +67% | +$956K | 0.48% | 52 |
|
|
2025
Q4 | $1.48M | Buy |
6,474
+335
| +5% | +$76.3K | 0.29% | 90 |
|
|
2025
Q3 | $1.42M | Buy |
6,139
+2
| +0% | +$407 | 0.28% | 95 |
|
|
2025
Q2 | $1.14M | Buy |
6,137
+2
| +0% | +$372 | 0.25% | 113 |
|
|
2025
Q1 | $1.29M | Buy |
6,135
+9
| +0.1% | +$1.75K | 0.32% | 94 |
|
|
2024
Q4 | $1.09M | Sell |
6,126
-5
| -0.1% | -$919 | 0.24% | 106 |
|
|
2024
Q3 | $1.21M | Sell |
6,131
-4,408
| -42% | -$823K | 0.31% | 96 |
|
|
2024
Q2 | $1.81M | Buy |
10,539
+4,931
| +88% | +$817K | 0.49% | 57 |
|
|
2024
Q1 | $1.02M | Sell |
5,608
-7,187
| -56% | -$1.24M | 0.27% | 106 |
|
|
2023
Q4 | $1.98M | Sell |
12,795
-37
| -0.3% | -$5.39K | 0.57% | 50 |
|
|
2023
Q3 | $1.91M | Sell |
12,832
-13
| -0.1% | -$1.91K | 0.61% | 45 |
|
|
2023
Q2 | $1.73M | Buy |
12,845
+27
| +0.2% | +$3.96K | 0.52% | 49 |
|
|
2023
Q1 | $2.04M | Buy |
12,818
+1,598
| +14% | +$244K | 0.65% | 43 |
|
|
2022
Q4 | $1.81M | Buy |
11,220
+58
| +0.5% | +$8.89K | 0.63% | 44 |
|
|
2022
Q3 | $1.5M | Sell |
11,162
-346
| -3% | -$49.7K | 0.53% | 53 |
|
|
2022
Q2 | $1.76M | Sell |
11,508
-800
| -6% | -$122K | 0.61% | 42 |
|
|
2022
Q1 | $2M | Buy |
12,308
+2,845
| +30% | +$413K | 0.6% | 43 |
|
|
2021
Q4 | $1.28M | Sell |
9,463
-20
| -0.2% | -$2.36K | 0.33% | 80 |
|
|
2021
Q3 | $1.02M | Buy |
9,483
+173
| +2% | +$19.8K | 0.25% | 108 |
|
|
2021
Q2 | $1.05M | Buy |
9,310
+5,075
| +120% | +$572K | 0.24% | 116 |
|
|
2021
Q1 | $458K | Sell |
4,235
-7,994
| -65% | -$855K | 0.13% | 185 |
|
|
2020
Q4 | $1.31M | Sell |
12,229
-660
| -5% | -$63.4K | 0.39% | 78 |
|
|
2020
Q3 | $1.13M | Sell |
12,889
-1,984
| -13% | -$187K | 0.43% | 70 |
|
|
2020
Q2 | $1.46M | Buy |
+14,873
| New | +$1.31M | 0.57% | 43 |
|
|
2020
Q1 | – | Sell |
-12,191
| Closed | -$1.08M | – | 194 |
|
|
2019
Q4 | $1.08M | Buy |
12,191
+404
| +3% | +$33.5K | 0.44% | 63 |
|
|
2019
Q3 | $893K | Buy |
11,787
+2,313
| +24% | +$159K | 0.39% | 75 |
|
|
2019
Q2 | $689K | Buy |
9,474
+1,200
| +15% | +$94.3K | 0.3% | 97 |
|
|
2019
Q1 | $667K | Buy |
8,274
+1,625
| +24% | +$133K | 0.29% | 99 |
|
|
2018
Q4 | $613K | Sell |
6,649
-803
| -11% | -$70.6K | 0.42% | 62 |
|
|
2018
Q3 | $705K | Buy |
7,452
+651
| +10% | +$61.7K | 0.25% | 118 |
|
|
2018
Q2 | $630K | Buy |
6,801
+1,175
| +21% | +$115K | 0.23% | 117 |
|
|
2018
Q1 | $533K | Buy |
5,626
+4,314
| +329% | +$474K | 0.18% | 131 |
|
|
2017
Q4 | $127K | Hold |
1,312
| – | – | 0.05% | 262 |
|
|
2017
Q3 | $117K | Hold |
1,312
| – | – | 0.05% | 279 |
|
|
2017
Q2 | $95K | Buy |
1,312
+378
| +40% | +$25.4K | 0.04% | 278 |
|
|
2017
Q1 | $61K | Hold |
934
| – | – | 0.03% | 303 |
|
|
2016
Q4 | $58K | Buy |
+934
| New | +$57K | 0.03% | 294 |
|
Other funds holding ABBV
Intellectus Partners's ABBV Position: Q2 2026 in Review
Intellectus Partners increased its AbbVie (ABBV) stake by 7.5% in Q2 2026, buying an estimated $174K and bringing the position to 11,595 shares worth $2.92M. The position accounts for 0.5% of the portfolio, ranked #42.
Intellectus Partners first reported a position in ABBV in Q4 2016 and has held it in 38 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Intellectus Partners held 11,595 shares of AbbVie worth $2.92M as of Q2 2026.
- Intellectus Partners bought 811 AbbVie shares in Q2 2026, an estimated $174K.
- AbbVie made up 0.5% of Intellectus Partners's portfolio in Q2 2026, its #42 holding.
- Intellectus Partners first reported a position in AbbVie in Q4 2016 and has held it in 38 quarters since.
- 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Intellectus Partners's 13F filing for Q2 2026, filed 12 Aug 2026.